Paperbase

Matthias G. Pauthner

Pauthner Matthias G.

ORCID: 0000-0001-9212-4307

Global site-specific N-glycosylation analysis of HIV envelope glycoprotein 10.1038/ncomms14954

Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding 10.1038/s41467-017-01549-6

Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer 10.1038/s41467-018-06121-4

Vaccine-induced protection from homologous Tier 2 simian-human immunodeficiency virus challenge in nonhuman primates 10.1101/454769

Neutralizing antibody responses to an HIV envelope glycan hole are not easily broadened 10.1101/827477

HIV Envelope Trimer-Elicited Autologous Neutralizing Antibodies Bind a Region Overlapping the N332 Glycan Supersite 10.1101/831008

HIV envelope trimer-elicited autologous neutralizing antibodies bind a region overlapping the N332 glycan supersite 10.1126/sciadv.aba0512

Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization 10.1016/j.immuni.2018.07.009

A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans 10.1016/j.immuni.2016.06.026

A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure 10.1016/j.immuni.2017.03.017

Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers 10.1016/j.immuni.2018.11.011

Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches 10.1016/j.immuni.2017.05.007

Mapping Neutralizing Antibody Epitope Specificities to an HIV Env Trimer in Immunized and in Infected Rhesus Macaques 10.1016/j.celrep.2020.108122

The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template 10.1016/j.celrep.2019.04.082

Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies 10.1016/j.celrep.2016.07.074

Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer 10.1016/j.celrep.2016.10.085

A Fc-Engineering Approach to Define Functional Humoral Correlates of Immunity Against Ebola Virus 10.2139/ssrn.3608385

Mapping Neutralizing Antibody Epitope Specificities to an HIV Env Trimer in Immunized and in Infected Rhesus Macaques 10.2139/ssrn.3641803

Correction: Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design 10.1371/journal.ppat.1005905

Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design 10.1371/journal.ppat.1005815

Vaccine-induced immune responses against both Gag and Env improve control of simian immunodeficiency virus replication in rectally challenged rhesus macaques 10.1371/journal.ppat.1006529

Autologous Antibody Responses to an HIV Envelope Glycan Hole Are Not Easily Broadened in Rabbits 10.1128/jvi.01861-19

Rectal Acquisition of SIVmac239 Infection Despite Vaccine-Induced Immune Responses Against the Entire SIV Proteome 10.1128/jvi.00979-20

Mamu-B*17+ Rhesus Macaques Vaccinated with env, vif, and nef Manifest Early Control of SIVmac239 Replication 10.1128/jvi.00690-18

Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen 10.1126/science.aac5894

Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice 10.1126/science.aah3945

Lassa Virus Genetics 10.1007/82_2020_212

Antibody engineering & therapeutics, the annual meeting of the antibody society December 7–10, 2015, San Diego, CA, USA 10.1080/19420862.2016.1153211

Mapping Neutralizing Antibody Epitope Specificities to an HIV Env Trimer in Immunized and in Infected Rhesus Macaques 10.2139/ssrn.3578689

Harnessing Activin A Adjuvanticity to Promote Antibody Responses to BG505 HIV Envelope Trimers 10.3389/fimmu.2020.01213

Global site-specific analysis of glycoprotein N-glycan processing 10.1038/nprot.2018.024

CodY orchestrates the expression of virulence determinants in emetic Bacillus cereus by impacting key regulatory circuits 10.1111/j.1365-2958.2012.08090.x

A Recombinant HIV Envelope Trimer Selects for Quaternary Dependent Antibodies Targeting the Trimer Apex 10.1089/aid.2014.5002.abstract

Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes 10.1016/j.virol.2014.10.032

Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex 10.1073/pnas.1415789111

Corrigendum to: Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes [Virology 475 (2015) 37–45] 10.1016/j.virol.2015.01.023

Antibody Engineering and Therapeutics 10.4161/mabs.28421

Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance 10.1016/j.cell.2019.12.027

Induction of Transient Virus Replication Facilitates Antigen-Independent Isolation of SIV-Specific Monoclonal Antibodies 10.1016/j.omtm.2020.01.010

An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability 10.1038/nmicrobiol.2016.199

A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge 10.1016/j.chom.2019.08.014

Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance 10.1016/j.cell.2019.04.012

Chimpanzee SIV Envelope trimer: structure and deployment as an HIV vaccine template 10.1101/459164

Slow delivery immunization enhances HIV neutralizing antibody and germinal center responses via modulation of immunodominance 10.1101/432666

Aaron Oom

Oom Aaron / Aaron L. Oom

ORCID: 0000-0003-3300-0333

MicroRNAs: Novel Players in Cancer Diagnosis and Therapies 10.1155/2014/959461

MicroRNA-200b targets protein kinase C and suppresses triple-negative breast cancer metastasis 10.1093/carcin/bgu133

Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. 10.1016/j.immuni.2017.05.007

Identification of putative unique immunogenic ZIKV and DENV1-4 peptides for diagnostic cellular based tests 10.1038/s41598-017-05980-z

Untargeted mass spectrometry-based metabolomics approach unveils molecular changes in raw and processed foods and beverages 10.1016/j.foodchem.2019.125290

Comparative Analysis of T Cell Spatial Proteomics and the Influence of HIV Expression 10.1101/2021.03.17.435902

Interactions of SARS-CoV-2 envelope protein with amilorides correlate with antiviral activity 10.1101/2021.04.06.438579

Interactions of SARS-CoV-2 envelope protein with amilorides correlate with antiviral activity 10.1371/journal.ppat.1009519

Abishek Chandrashekar

Chandrashekar Abishek / Abi Chandrashekar

ORCID: 0000-0001-7821-5552

Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against re-infection with B.1.1.7 and B.1.351 variants 10.1126/scitranslmed.abj2641

Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys 10.1126/science.aah6157

Erratum to: Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys (Nature, (2018), 563, 7731, (360-364), 10.1038/s41586-018-0600-6) 10.1038/s41586-018-0721-y

Durability and correlates of vaccine protection against Zika virus in rhesus monkeys 10.1126/scitranslmed.aao4163

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19) 10.1016/S0140-6736(18)31364-3

Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys 10.1016/j.cell.2017.04.008

Virological control by the CD4-binding site antibody N6 in simian-human immunodeficiency virus-infected rhesus monkeys 10.1128/JVI.00498-17

Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys 10.1038/nature20583

Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus 10.1126/science.aag0491

Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys 10.1038/s41586-018-0600-6

Erratum: Durability and correlates of vaccine protection against Zika virus in rhesus monkeys (Science Translational Medicine DOI: 10.1126/scitranslmed.aao4163) 10.1126/scitranslmed.aau6861

Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches 10.1016/j.immuni.2017.05.007

Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens 10.1016/j.vaccine.2016.11.063

Investigations into nicotinic Stat3 signaling using a luciferase reporter plasmid 10.1016/j.bcp.2011.07.031

Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17–22) https://doi.org/10.1016/s2352-3018(20)30001-1

Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17–22) 10.1016/s2352-3018(20)30001-1

Lack of therapeutic efficacy of an antibody to α4β7 in SIVmac251-infected rhesus macaques 10.1126/science.aaw8562

Differential Outcomes Following Optimization of Simian-Human Immunodeficiency Viruses From Clades AE, B and C 10.1128/jvi.01860-19

Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial 10.1016/S1473-3099(20)30085-2

DNA vaccine protection against SARS-CoV-2 in rhesus macaques 10.1126/science.abc6284

SARS-CoV-2 infection protects against rechallenge in rhesus macaques 10.1126/science.abc4776

Sustained maternal antibody and cellular immune responses in pregnant women infected with Zika virus and mother to infant transfer of Zika‐specific antibodies 10.1111/aji.13288

Potently neutralizing and protective human antibodies against SARS-CoV-2 10.1038/s41586-020-2548-6

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques 10.1038/s41586-020-2607-z

Origin of rebound virus in chronically SIV-infected Rhesus monkeys following treatment discontinuation 10.1038/s41467-020-19254-2

Correlates of protection against SARS-CoV-2 in rhesus macaques 10.1038/s41586-020-03041-6

Publisher Correction: Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques 10.1038/s41586-020-03100-y

Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques 10.1101/2021.01.27.428380

Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques 10.1038/s41467-021-21724-0

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans 10.1038/s41586-021-03681-2

Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques 10.1038/s41586-021-03732-8

Impact of prior Dengue immunity on Zika vaccine protection in rhesus macaques and mice 10.1371/journal.ppat.1009673

Laura McCoy

McCoy Laura

ORCID: 0000-0001-9503-7946

https://twitter.com/RealMcCoyLab

https://www.ucl.ac.uk/infection-immunity/people/dr-laura-mccoy

Reprogramming the antigen specificity of B cells using genome-editing technologies 10.1101/455402

The expanding array of HIV broadly neutralizing antibodies. 10.1186/s12977-018-0453-y

Human Immunodeficiency Virus (HIV)-Antibody Repertoire Estimates Reservoir Size and Time of Antiretroviral Therapy Initiation in Virally Suppressed Perinatally HIV-Infected Children. 10.1093/jpids/piy080

Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization. 10.1016/j.immuni.2018.07.009

Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. 10.1371/journal.ppat.1006986

Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model. 10.1016/j.celrep.2017.10.089

Unravelling the Molecular Basis of High Affinity Nanobodies against HIV p24: In Vitro Functional, Structural, and in Silico Insights. 10.1021/acsinfecdis.6b00189

Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. 10.1016/j.immuni.2017.05.007

Lessons learned from humoral responses of HIV patients. 10.1097/coh.0000000000000361

Identification and specificity of broadly neutralizing antibodies against HIV. 10.1111/imr.12484

HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. 10.1016/j.immuni.2016.08.016

Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies. 10.1016/j.celrep.2016.07.074

Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design. 10.1016/j.immuni.2015.10.014

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies. 10.1371/journal.ppat.1005110

Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas. 10.1128/mbio.00296-15

Molecular evolution of broadly neutralizing Llama antibodies to the CD4-binding site of HIV-1. 10.1371/journal.ppat.1004552

Neutralisation of HIV-1 cell-cell spread by human and llama antibodies. 10.1186/s12977-014-0083-y

A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 for neutralization but not for antigen recognition. 10.1371/journal.ppat.1003202

Neutralizing antibodies to HIV-1 induced by immunization. 10.1084/jem.20121827

Broad and potent neutralization of HIV-1 by human-llama fusion antibodies derived from immunized llamas. 10.1186/1742-4690-9-S2-P94

A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 determinant for neutralization but not for antigen recognition. 10.1186/1742-4690-9-S2-P317

Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. 10.1084/jem.20112655

Circulating and intrahepatic antiviral B cells are defective in hepatitis B. 10.1172/JCI121960

Mapping the IkappaB kinase beta (IKKbeta)-binding interface of the B14 protein, a vaccinia virus inhibitor of IKKbeta-mediated activation of nuclear factor kappaB. 10.1074/jbc.M111.231381

Mutations in modified virus Ankara protein 183 render it a non-functional counterpart of B14, an inhibitor of nuclear factor kappaB activation. 10.1099/vir.0.022343-0

The impact of Spike mutations on SARS-CoV-2 neutralization 10.1101/2021.01.15.426849

Kai Post

Post Kai

ORCID: 0000-0003-1002-3989

Benchmarking blockchain-based gene-drug interaction data sharing methods: A case study from the iDASH 2019 secure genome analysis competition blockchain track. 10.1016/j.ijmedinf.2021.104559

Structural analysis of a set of proteins resulting from a bacterial genomics project. 10.1002/prot.20541

Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. 10.1016/j.immuni.2017.05.007

Cancer3D 2.0: interactive analysis of 3D patterns of cancer mutations in cancer subsets. 10.1093/nar/gky1098

bNAber: database of broadly neutralizing HIV antibodies. 10.1093/nar/gkt1083

Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator. 10.1038/sj.emboj.7600040

A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. 10.1074/jbc.m409792200

Molecular analysis of the SNF2/SWI2 protein family member MOT1, an ATP-driven enzyme that dissociates TATA-binding protein from DNA. 10.1128/mcb.17.8.4842